TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severe redness after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Severe swelling after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: finger pulp blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: RI (Resistive Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: periungual vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VAS Pain Intensity (Now)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASS values (pain anxiety symptoms)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bend Forward to Floor (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic steatosis measured by L/S ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Prevalence of fatty liver disease (FLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Spontaneous vaginal delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in scores from pretest to posttest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endurance of left extension at a speed of 60°/s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak torque of left dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: endurance of left plantar flexion at a speed of 60°/s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Healing percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean minutes of MVPA per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second-phase insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Straylight values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of used serum for bladder irrigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microscopic status of urine in terms of hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDAI score decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDEIS score decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDEIS remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter placement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Material costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative analgesic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of symptomatic recurrent lumbar disc herniation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of antimalarials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health-related Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hospital Anxiety and Depression Scales (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nonvertebral fracture risk
Endpoint domain: Adverse events/effects
Primary endpoint: CRE colonisation and infections detection rates
Endpoint domain: Adverse events/effects
Primary endpoint: CSF white cell count (WCC) ≥5/µL at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful eruption of PDCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in arch perimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of anxiety or depressive disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Incremental cost per quality-adjusted life-year (QALY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inhibition of histamine-induced wheal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of histamine-induced flare response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to disease relapse (TTDR)
Endpoint domain: Mortality/survival
Primary endpoint: Average post-operative length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: AUC∞ for saxagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC∞ for 5-hydroxy saxagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: risk of nasal allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: atopic sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary morbidity (DeltaAUA score change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Infarction (MI) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-density lipoprotein (HDL) cholesterol change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-handicapping scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of screening-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to routine activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited local and systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Facial nerve function exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glossopharyngeal nerve function deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hypoglossal nerve function deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Upper level of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensory evoked potentials (SEPs) abolition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin resistance responses (SRRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of pullbacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of EPS-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Median Time to Onset (TTO) of EPS-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Median Time to Resolution (TTR) of EPS-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hot flash scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma trypsinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraduodenal pancreatic fluid secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic properties of EE and DRSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal microperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percentage of patients with complete headache relief at 2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weighted pain intensity difference at 3 and 6h (SPID‐3; SPID‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nights awakened with asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-S scale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: goal weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: goal HbA1C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: goal blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from AF recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Smoking initiation
Endpoint domain: Mortality/survival
Primary endpoint: LEP peak-to-peak amplitudes reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depersonalization reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary symptom reduction on MYMOP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: N100 latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P200 latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P3a amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Polyp size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pinprick sensory block height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first recurrence of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mechanical pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amnesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hippocampal response suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daily headache scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reflective ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: Medical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebro‐Vascular Function Scores (CVFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to CPR instructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Haematocrit value during cardiopulmonary bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic availability of free EGCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in treating OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients needing rescue propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipid accumulation product index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ultra sensitive C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conspicuity of tumor margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of residual or recurrent tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal nonreactive concentrations of NMBAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in total and LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dietary intake of saturated fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutrient drinking-induced fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: objS occurrence after AIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sIgG4 levels in active group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achieving hemostasis at 4 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adjustment in social environment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: VABS‐II functional performance composite scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: awareness rate of prevention and control knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evening trough FEV1 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diarrhea and abdominal discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: AIR insulin exposure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GP IIb/IIIa expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P-selectin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: horizontal volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated propofol plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotonin‐1A receptor binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CGA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1C level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac index (CI) percentage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular ejection fraction (RVEF) percentage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of babies with nicotine in hair samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of post-operative pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: Actuarial patient/graft survival at 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Mean estimated glomerular filtration rate at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: performance enhancement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gingival overgrowth index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal ovulatory cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: median pseudomonas-free survival period
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of SRAEs
Endpoint domain: Adverse events/effects
Primary endpoint: cystatin C‐based eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: superior phosphate response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of anaemia
Endpoint domain: Adverse events/effects
Primary endpoint: physician- and patient-reported disease outcomes
Endpoint domain: Life impact
Primary endpoint: EEG seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak heart rate after ECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean facial bone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrence in decision of administering TMZ
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median cost incurred in VF vs CF
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neck muscle strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time expenditure for medication reconciliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in median VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in prevalence of multiple risk factors for colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problems of sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Gynecologic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stable disease for greater than 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of Transmitted Drug Resistance (TDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Nutritional Assessment (MNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Edinburgh Feeding Evaluation in Dementia (EdFED) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antithrombin III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Metalloproteinase‐9/tissue inhibitor of metalloproteinase‐1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: E-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RE activation during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol-AUC24 suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intraobserver reliability for qualitative evaluation of strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver reliability for qualitative evaluation of strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-catheter reliability for qualitative evaluation of strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from discontinuation to analeptic and extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: sIgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hsCRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of tumour necrosis factor‐α blockade
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: supervisors' competency levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased campesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inverse linear relationships between free 25‐OH D and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inverse linear relationships between free 25‐OH D and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dentoalveolar width changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes